A retrospective analysis of the impact of treatments and blood counts on survival and the risk of vascular events during the course of polycythaemia vera

Anneli Enblom‐Larsson(Umeå University), Björn Andréasson(NU Hospital Group), François Girodon(Inserm), Peter Johansson(Linköping University), Hans Carl Hasselbalch(Zealand University Hospital), Valérie Jooste(Inserm), Marie Bak(Zealand University Hospital), Ditte Stampe Hersby(Copenhagen University Hospital)

British Journal of Haematology

May 5, 2017

10.1111/bjh.14625

Cited by 14

Related Papers

Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs

|Journal of Clinical Oncology|2012|461

Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study

|The Lancet Haematology|2020|351

The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patients

|Blood|2011|340

A prognostic model to predict survival in 867 World Health Organization–defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment

|Blood|2012|270

Treatment-Related Risk Factors for Transformation to Acute Myeloid Leukemia and Myelodysplastic Syndromes in Myeloproliferative Neoplasms

|Journal of Clinical Oncology|2011|244